局部晚期直肠癌多模式治疗期间连续循环肿瘤DNA分析:一项前瞻性生物标志物研究
这项前瞻性研究纳入159例计划接受新辅助放化疗的局部晚期直肠癌(LARC)患者,分析462份系列血浆样本,发现术后ctDNA阳性者3年无复发生存率为33%,阴性者为87%,术后ctDNA状态是独立于常规临床病理危险因素的复发预测因子,作者认为ctDNA分析可能用于指导辅助化疗的患者选择。
要点
- 术后ctDNA阳性患者3年无复发生存率为33%,阴性者为87%。
- 术后ctDNA检测预测复发独立于辅助化疗使用(化疗HR 10.0,未化疗HR 22.0)。
- 校正已知临床病理危险因素后,术后ctDNA状态仍为无复发生存独立预测因子(HR 6.0)。
核心结论
- 术后ctDNA分析可将LARC患者分为复发风险极高和极低两个亚组,且独立于常规临床病理危险因素。
- 作者认为ctDNA分析可能用于指导辅助化疗的患者选择。
研究设计与样本
- 前瞻性生物标志物研究,纳入计划接受新辅助放化疗的LARC患者(T3/T4和/或N+)。
- 在治疗前、放化疗后和术后4-10周采集血浆样本,通过15个结直肠癌常见突变基因的大规模平行测序鉴定个体肿瘤体细胞突变,并设计个性化检测定量血浆ctDNA。
- 患者由临床医生决定接受辅助治疗,且对ctDNA结果设盲。
主要发现
- 共分析159例患者的462份系列血浆样本。
- 治疗前、放化疗后和术后血浆样本中ctDNA可检出率分别为77%、8.3%和12%。
- 放化疗后可检出ctDNA者无复发生存显著更差(HR 6.6;P<0.001),术后可检出者亦显著更差(HR 13.0;P<0.001)。
- 术后ctDNA阳性患者估计3年无复发生存率为33%,阴性者为87%。
- 术后ctDNA检测预测复发独立于辅助化疗使用(化疗:HR 10.0;P<0.001;未化疗:HR 22.0;P<0.001)。
临床怎么用
- 作者认为ctDNA分析可能用于指导LARC患者辅助化疗的选择。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in patients with LARC. DESIGN: We enrolled patients with LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4-10 weeks after surgery. Somatic mutations in individual patient's tumour were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. We then designed personalised assays to quantify ctDNA in plasma samples. Patients received adjuvant therapy at clinician discretion, blinded to the ctDNA results. RESULTS: We analysed 462 serial plasma samples from 159 patients. ctDNA was detectable in 77%, 8.3% and 12% of pretreatment, postchemoradiotherapy and postsurgery plasma samples. Significantly worse recurrence-free survival was seen if ctDNA was detectable after chemoradiotherapy (HR 6.6; P<0.001) or after surgery (HR 13.0; P<0.001). The estimated 3-year recurrence-free survival was 33% for the postoperative ctDNA-positive patients and 87% for the postoperative ctDNA-negative patients. Postoperative ctDNA detection was predictive of recurrence irrespective of adjuvant chemotherapy use (chemotherapy: HR 10.0; P<0.001; without chemotherapy: HR 22.0; P<0.001). Postoperative ctDNA status remained an independent predictor of recurrence-free survival after adjusting for known clinicopathological risk factors (HR 6.0; P<0.001). CONCLUSION: Postoperative ctDNA analysis stratifies patients with LARC into subsets that are either at very high or at low risk of recurrence, independent of conventional clinicopathological risk factors. ctDNA analysis could potentially be used to guide patient selection for adjuvant chemotherapy.
引用
- Tie J, Cohen JD, Wang Y, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2018. PMID: 29420226. doi:10.1136/gutjnl-2017-315852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。